EVM
UTHR icon

Eaton Vance Management’s United Therapeutics UTHR Stock Holding History

Eaton Vance Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$3.71M Buy
17,715
+27
+0.2% +$6.04K 0.01% 861
2022
Q2 		$4.17M Sell
17,688
-1,365
-7% -$278K 0.01% 866
2022
Q1 		$3.42M Buy
19,053
+18,428
+2,948% +$3.51M ﹤0.01% 1004
2021
Q4 		$135K Sell
625
-1
-0.2% -$196 ﹤0.01% 1720
2021
Q3 		$0 Sell
626
-541
-46% -$107K ﹤0.01% 2693
2021
Q2 		$210K Buy
1,167
+990
+559% +$189K ﹤0.01% 1588
2021
Q1 		$30K Buy
+177
New +$29.5K ﹤0.01% 1937
2019
Q2 		– Sell
-2,139
Closed -$251K – 1315
2019
Q1 		$251K Sell
2,139
-125
-6% -$14.6K ﹤0.01% 1174
2018
Q4 		$247K Sell
2,264
-568
-20% -$65.9K ﹤0.01% 1123
2018
Q3 		$362K Sell
2,832
-285
-9% -$35.3K ﹤0.01% 1090
2018
Q2 		$353K Sell
3,117
-3,163
-50% -$348K ﹤0.01% 1066
2018
Q1 		$706K Buy
6,280
+2,357
+60% +$299K ﹤0.01% 1034
2017
Q4 		$580K Sell
3,923
-238
-6% -$30.3K ﹤0.01% 938
2017
Q3 		$488K Sell
4,161
-1
-0% -$128 ﹤0.01% 954
2017
Q2 		$540K Sell
4,162
-54
-1% -$6.74K ﹤0.01% 925
2017
Q1 		$571K Sell
4,216
-1,980
-32% -$300K ﹤0.01% 877
2016
Q4 		$889K Buy
6,196
+63
+1% +$8.04K ﹤0.01% 749
2016
Q3 		$724K Sell
6,133
-18
-0.3% -$2.16K ﹤0.01% 783
2016
Q2 		$652K Sell
6,151
-2,432
-28% -$271K ﹤0.01% 770
2016
Q1 		$956K Buy
8,583
+223
+3% +$28.2K ﹤0.01% 685
2015
Q4 		$1.31M Buy
8,360
+860
+11% +$125K ﹤0.01% 629
2015
Q3 		$984K Hold
7,500
– – ﹤0.01% 674
2015
Q2 		$1.3M Hold
7,500
– – ﹤0.01% 592
2015
Q1 		$1.29M Buy
+7,500
New +$1.14M ﹤0.01% 629

Other funds holding UTHR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Eaton Vance Management's UTHR Position: Q3 2022 in Review

Eaton Vance Management increased its United Therapeutics (UTHR) stake by 0.15% in Q3 2022, buying an estimated $6.04K and bringing the position to 17,715 shares worth $3.71M. The position accounts for 0.01% of the portfolio, ranked #861.

Eaton Vance Management first reported a position in UTHR in Q1 2015 and has held it in 24 quarters since. The position peaked at $4.17M in Q2 2022. 461 funds tracked by Wall St. Rank hold UTHR as of Q3 2022.

  • Eaton Vance Management held 17,715 shares of United Therapeutics worth $3.71M as of Q3 2022.
  • Eaton Vance Management bought 27 United Therapeutics shares in Q3 2022, an estimated $6.04K.
  • United Therapeutics made up 0.01% of Eaton Vance Management's portfolio in Q3 2022, its #861 holding.
  • Eaton Vance Management first reported a position in United Therapeutics in Q1 2015 and has held it in 24 quarters since.
  • Eaton Vance Management's United Therapeutics position peaked at $4.17M in Q2 2022.
  • 461 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2022.

Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.